'''25N-NBOMe''' ('''2C-N-NBOMe''', '''NBOMe-2C-N''') is a [[derivative (chemistry)|derivative]] of the [[hallucinogen]] [[2C-N]]. The pharmacological properties of 25N-NBOMe have not been described in the scientific literature, but it is believed to act in a similar manner to related compounds such as [[25I-NBOMe]] and [[25C-NBOMe]], which are potent [[agonist]]s at the [[5HT2A receptor|5HT<sub>2A</sub>]] [[Receptor (biochemistry)|receptor]].<ref>{{Cite doi|10.1021/cn400216u}}</ref><ref>[http://bitnest.ca/external.php?id=%2518%253A3%25172%251BE%2524K%255BG%2521%2524%257D%2504%2504V Hansen, M. Design and Synthesis of Selective Serotonin Receptor Agonists for Positron Emission Tomography Imaging of the Brain. PhD Thesis, University of Copenhagen, 2011.]</ref> 25N-NBOMe has been sold as a street drug and has only been described in the literature in terms of identification by forensic analysis.<ref>{{cite journal|last=Casale|first=John F.|author2=Hays, Patrick A.|title=Characterization of Eleven 2,5-Dimethoxy-N-(2-methoxybenzyl)phenethylamine (NBOMe) Derivatives and Differentiation from their 3- and 4-Methoxybenzyl Analogues - Part I|journal=Microgram Journal|year=2012|volume=9|issue=2|pages=84–109|url=http://www.justice.gov/dea/pr/microgram-journals/2012/mj9_84-109.pdf|accessdate=14 January 2014}}</ref>
'''25N-NBOMe''' ('''2C-N-NBOMe''', '''NBOMe-2C-N''') is a [[derivative (chemistry)|derivative]] of the [[hallucinogen]] [[2C-N]]. The pharmacological properties of 25N-NBOMe have not been described in the scientific literature, but it is believed to act in a similar manner to related compounds such as [[25I-NBOMe]] and [[25C-NBOMe]], which are potent [[agonist]]s at the [[5HT2A receptor|5HT<sub>2A</sub>]] [[Receptor (biochemistry)|receptor]].<ref>{{Cite doi|10.1021/cn400216u}}</ref><ref>[http://bitnest.ca/external.php?id=%2518%253A3%25172%251BE%2524K%255BG%2521%2524%257D%2504%2504V Hansen, M. Design and Synthesis of Selective Serotonin Receptor Agonists for Positron Emission Tomography Imaging of the Brain. PhD Thesis, University of Copenhagen, 2011.]</ref> 25N-NBOMe has been sold as a street drug and has only been described in the literature in terms of identification by forensic analysis.<ref>{{cite journal|last=Casale|first=John F.|author2=Hays, Patrick A.|title=Characterization of Eleven 2,5-Dimethoxy-N-(2-methoxybenzyl)phenethylamine (NBOMe) Derivatives and Differentiation from their 3- and 4-Methoxybenzyl Analogues - Part I|journal=Microgram Journal|year=2012|volume=9|issue=2|pages=84–109|url=http://www.justice.gov/dea/pr/microgram-journals/2012/mj9_84-109.pdf|accessdate=14 January 2014}}</ref>
==Legality==
Sweden's public health agency suggested to classify 25N-NBOMe as hazardous substance on November 10, 2014.<ref>{{cite web | url=http://www.folkhalsomyndigheten.se/nyheter-och-press/nyhetsarkiv/2014/november/cannabinoider-foreslas-bli-klassade-som-halsofarlig-vara/ | title=Cannabinoider föreslås bli klassade som hälsofarlig vara | accessdate=29 June 2015}}</ref>
25N-NBOMe (2C-N-NBOMe, NBOMe-2C-N) is a derivative of the hallucinogen2C-N. The pharmacological properties of 25N-NBOMe have not been described in the scientific literature, but it is believed to act in a similar manner to related compounds such as 25I-NBOMe and 25C-NBOMe, which are potent agonists at the 5HT2Areceptor.[1][2] 25N-NBOMe has been sold as a street drug and has only been described in the literature in terms of identification by forensic analysis.[3]
Legality
Sweden's public health agency suggested to classify 25N-NBOMe as hazardous substance on November 10, 2014.[4]
^Attention: This template ({{cite doi}}) is deprecated. To cite the publication identified by doi:10.1021/cn400216u, please use {{cite journal}} (if it was published in a bona fide academic journal, otherwise {{cite report}} with |doi=10.1021/cn400216u instead.
